Assay turnaround time and tumor board recommendations for feasibility cohort
| . | No. . | % . | Median . | Range . |
|---|---|---|---|---|
| Turnaround time from study bone marrow biopsy, d | ||||
| NGS panel (596 genes) | 14.5 | 8-30 | ||
| Ex vivo drug sensitivity screen | 15 | 13-24 | ||
| Drug recommendations from tumor board* | ||||
| HMA + venetoclax | 10 | 48 | ||
| Calcitriol (single agent or in combination) | 8 | 38 | ||
| Sorafenib (single agent or in combination) | 5 | 24 | ||
| Tretinoin (single agent or in combination) | 5 | 24 | ||
| Cytarabine + venetoclax | 4 | 19 | ||
| Lenalidomide | 4 | 19 | ||
| Ruxolitinib (single agent or in combination) | 3 | 14 | ||
| Danazol (in combination with tretinoin or calcitriol) | 3 | 14 | ||
| Panobinostat (single agent or in combination) | 3 | 14 | ||
| Ixazomib + dexamethasone | 2 | 10 | ||
| Midostaurin (single agent or in combination) | 2 | 10 | ||
| Everolimus | 2 | 10 |
| . | No. . | % . | Median . | Range . |
|---|---|---|---|---|
| Turnaround time from study bone marrow biopsy, d | ||||
| NGS panel (596 genes) | 14.5 | 8-30 | ||
| Ex vivo drug sensitivity screen | 15 | 13-24 | ||
| Drug recommendations from tumor board* | ||||
| HMA + venetoclax | 10 | 48 | ||
| Calcitriol (single agent or in combination) | 8 | 38 | ||
| Sorafenib (single agent or in combination) | 5 | 24 | ||
| Tretinoin (single agent or in combination) | 5 | 24 | ||
| Cytarabine + venetoclax | 4 | 19 | ||
| Lenalidomide | 4 | 19 | ||
| Ruxolitinib (single agent or in combination) | 3 | 14 | ||
| Danazol (in combination with tretinoin or calcitriol) | 3 | 14 | ||
| Panobinostat (single agent or in combination) | 3 | 14 | ||
| Ixazomib + dexamethasone | 2 | 10 | ||
| Midostaurin (single agent or in combination) | 2 | 10 | ||
| Everolimus | 2 | 10 |
Includes drugs or drug combinations recommended as first-, second-, or third-line therapy by the tumor board (a complete list of tumor board recommendations for each patient is provided in supplemental Table 3).